EU Project To Boost Capacity Of Medicines Regulatory Network

Those involved in the IncreaseNET initiative hope that providing more training for both new and experienced assessors will take the pressure off a regulatory network faced with a growing workload and a shortage of expertise in the face of new scientific developments.

Presentation, graphs or businessman by board for writing, growth stats or revenue in meeting.
Training of assessors is a key part of the EU initiative • Source: Shutterstock

Pharmaceutical industry representatives attending a recent meeting at the European Medicines Agency were updated on progress with an initiative intended to boost the capacity of the European medicines regulatory network (EMRN) and strengthen future collaboration among EU national competent authorities (NCAs).

More from Europe

EMA Recommends EU Approval For Averoa’s Xoanacyl And Four Other Drugs

 

The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.

European Regulator Deals Blow For Lilly’s Alzheimer’s Drug Kisunla

 

Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.

E6(R3) Introduces Flexibility And Challenges To Clinical Trial Documentation

 
• By 

The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.

German Ordinance To Implement HTA Reg Leaves Room For Doubt

 

A German ordinance implementing the EU Health Technology Assessment Regulation offers little clarity on how far joint clinical assessment reports should be considered by national authorities.

More from Agency Leadership

Government Pulls ‘For Sale’ Signs From US FDA’s White Oak Campus

 
• By 

The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.

US FDA Staffing Uncertainty Could Impact Upcoming User Fee Negotiations

 

FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.